Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Partnering In China – Slow Gains In Store?

Executive Summary

As more multinational drug makers divest/license their maturing or non-core assets to local Chinese firms, a fast pick-up in sales in China via these alliances does not always appear to be ensured, at least early on. Scrip delves into one such recent agreement between Lilly and 3SBio, one of China's most successful biotechs.

Advertisement

Related Content

AZ Sustains Strong China Growth Via Commercial Innovation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099752

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel